Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 03, 2021

Cancer Treatment May Impact Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
JAMA Oncol 2021 May 28;[EPub Ahead of Print], A Massarweh, N Eliakim-Raz, A Stemmer, A Levy-Barda, S Yust-Katz, A Zer, A Benouaich-Amiel, H Ben-Zvi, N Moskovits, B Brenner, J Bishara, D Yahav, B Tadmor, T Zaks, SM Stemmer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading